Tocilizumab (Actemra®)

DRUG3 trials

Sponsors

University of Athens, Lorenzo delSorbo, Sohag University

Conditions

Acute Hypoxemic Respiratory FailureInflammationRheumatoid ArthritisSystemic Juvenile Idiopathic ArthritisSystemic Juvenile Idiopathic Arthritis (sJIA)

Phase 2

Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study

RecruitingNCT07334379

Lorenzo delSorboAcute Hypoxemic Respiratory Failure

Start: 2025-10-20End: 2027-02-26Target: 60Updated: 2026-01-12

Unknown Phase

Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis

University of AthensInflammation, Rheumatoid Arthritis

Start: 2017-10-27End: 2020-12-31Target: 60Updated: 2020-04-03

Clinical Features and Treatment of Systemic JIA in Children

Not yet recruitingNCT07814963

Sohag UniversitySystemic Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (sJIA)

Start: 2026-10-01End: 2027-09-01Target: 50Updated: 2026-09-11

Related Papers

Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19.

2020-08-1850 citations

Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function.

2019-03-1143 citations